<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03684772</url>
  </required_header>
  <id_info>
    <org_study_id>CLS003-CO-PR-004</org_study_id>
    <nct_id>NCT03684772</nct_id>
  </id_info>
  <brief_title>Topical Ionic Contra-Viral Therapy in Actinic Keratosis</brief_title>
  <official_title>A Phase 2, Randomized, Double Blind, Vehicle Controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics and Safety of Topical Ionic Contra-Viral Therapy (ICVT) Comprised of Digoxin and Furosemide in Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maruho Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the pharmacodynamics and evaluate safety, tolerability and clinical efficacy of&#xD;
      ICVT comprised of digoxin and furosemide (dual agent), digoxin (single agent), furosemide&#xD;
      (single agent) in patients with AK.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clinical clearance (CCC) per field</measure>
    <time_frame>Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in AK-FAS (AK field assessment scale)</measure>
    <time_frame>Day 42</time_frame>
    <description>AK Grade 0-IV, the higher the number the more % area covered by AK</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator global score (IGS) of each field</measure>
    <time_frame>Day 126</time_frame>
    <description>This is a 7 point scale from -2 (significantly worse) to +4 (completely cured), higher values represent a better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evolution of one assigned target lesion in the field, assessed by dermoscopy</measure>
    <time_frame>Day 126</time_frame>
    <description>assessing erythema, scaling, pigmentation, and follicular plug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Field morphology</measure>
    <time_frame>Day 126</time_frame>
    <description>Change in lesion count per field</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standardized photography with Canfield VISIA or 2D photography and with Antera 3D camera</measure>
    <time_frame>Day 126</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biopsy biomarker</measure>
    <time_frame>Day 126</time_frame>
    <description>Analysis will be prerformed for the following biomarker: IFN-a. IFN-g, Ki-67</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biopsy biomarker</measure>
    <time_frame>Day 126</time_frame>
    <description>Analysis will be prerformed for the following biomarker: IFN-g</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biopsy biomarker</measure>
    <time_frame>Day 126</time_frame>
    <description>Analysis will be prerformed for the following biomarker: Ki-67</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biopsy biomarker</measure>
    <time_frame>Day 126</time_frame>
    <description>Analysis will be prerformed for the following biomarker: p53</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biopsy biomarker</measure>
    <time_frame>Day 126</time_frame>
    <description>Analysis will be prerformed for the following biomarker: MCM7(minichromosome maintenance protein 7)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biopsy biomarker</measure>
    <time_frame>Day 126</time_frame>
    <description>Analysis will be prerformed for the following biomarker:putrescene</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biopsy biomarker</measure>
    <time_frame>Day 126</time_frame>
    <description>Analysis will be prerformed for the following biomarker: spermidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biopsy biomarker</measure>
    <time_frame>Day 126</time_frame>
    <description>Analysis will be prerformed for the following biomarker: beta HPV types 5,8,15,20,24,38</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin swab markers</measure>
    <time_frame>Day 126</time_frame>
    <description>Swab analysis will be performed for beta HPV types 5,8,15,20,24,38.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events collected throughout the study</measure>
    <time_frame>Day 126</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECGs performed at Screening and End of Study</measure>
    <time_frame>Day 126</time_frame>
    <description>The following component will be assessed: Heart Rate (bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECGs performed at Screening and End of Study</measure>
    <time_frame>Day 126</time_frame>
    <description>The following component will be assessed: PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECGs performed at Screening and End of Study</measure>
    <time_frame>Day 126</time_frame>
    <description>The following component will be assessed: QRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECGs performed at Screening and End of Study</measure>
    <time_frame>Day 126</time_frame>
    <description>The following component will be assessed: QT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECGs performed at Screening and End of Study</measure>
    <time_frame>Day 126</time_frame>
    <description>The following component will be assessed: QTcB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECGs performed at Screening and End of Study</measure>
    <time_frame>Day 126</time_frame>
    <description>The following component will be assessed: QTcF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs performed at Screening and End of Study</measure>
    <time_frame>Day 42</time_frame>
    <description>The following will be assessed: Pulse Rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs performed at Screening and End of Study</measure>
    <time_frame>Day 42</time_frame>
    <description>The following will be assessed: Systolic blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs performed at Screening and End of Study</measure>
    <time_frame>Day 42</time_frame>
    <description>The following will be assessed: Diastolic blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs performed at Screening and End of Study</measure>
    <time_frame>Day 42</time_frame>
    <description>The following will be assessed: Temperature ( ÌŠ C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient diary on treatment application compliance, local tolerance and selfies photo</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>ICVT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digoxin and Furosemide (0.125%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Furosemide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furosemide (0.125%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Digoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digoxin (0.125%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICVT Topical Gel</intervention_name>
    <description>Digoxin and Furosemide (0.125%)</description>
    <arm_group_label>ICVT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide Topical Gel</intervention_name>
    <description>Furosemide (0.125%)</description>
    <arm_group_label>Furosemide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin Topical Gel</intervention_name>
    <description>Digoxin (0.125%)</description>
    <arm_group_label>Digoxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Topical Gel</intervention_name>
    <description>Vehicle Gel</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female subjects 18 years or older with verified condition of general good&#xD;
             health (with exception of AK)&#xD;
&#xD;
          -  Confirmed clinical AK diagnosis by dermatologist&#xD;
&#xD;
          -  Subjects must have at least 2 facial fields of at least 25 cmÂ² (but preferably &gt;35&#xD;
             cmÂ²) present at screening and baseline visit where more than 2 AK lesions are visible&#xD;
             in each field (preferably the forehead, temple or cheek)&#xD;
&#xD;
          -  Subjects must be able to participate and willing to give written informed consent and&#xD;
             to comply with the study restrictions&#xD;
&#xD;
          -  Subjects must be able to communicate well with the investigator in Dutch&#xD;
&#xD;
          -  Subjects willing to refrain from using other topical products in the treatment area,&#xD;
             or prohibited medication for the duration of the study&#xD;
&#xD;
          -  Subjects must be willing to limit sun exposure of the involved skin to the extent&#xD;
             vocationally possible&#xD;
&#xD;
          -  Subjects and their partners of childbearing potential must use effective&#xD;
             contraception, for the duration of the study and for 3 months after the last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have used or received any treatment for AK in the treatment area within 28 days prior&#xD;
             to enrollment (including topical medications, immunosuppressive or immunomodulating&#xD;
             agents, phototherapy, oral retinoids, or other therapies for AKs)&#xD;
&#xD;
          -  Have any current pathologically relevant skin conditions in the field area other than&#xD;
             AK (e.g. squamous cell carcinoma or basal cell carcinoma).&#xD;
&#xD;
          -  Have a known hypersensitivity to any of the investigational product ingredients,&#xD;
             including digoxin and furosemide.&#xD;
&#xD;
          -  Current use of systemic digoxin or furosemide.&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 3 months prior to&#xD;
             screening or more than 4 times a year&#xD;
&#xD;
          -  Loss or donation of blood over 500 mL within three months (males) or four months&#xD;
             (females) prior to screening or intention to donate blood or blood products during the&#xD;
             study.&#xD;
&#xD;
          -  If a woman of childbearing potential, pregnant, or breast-feeding, or planning to&#xD;
             become pregnant during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Rissmann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Human Drug Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Rissmann, PhD</last_name>
    <phone>+ 31 71 5246 400</phone>
    <email>clintrials@chdr.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Rissmann, PhD</last_name>
      <phone>+ 31 (0)71 5246400</phone>
      <email>clintrials@chdr.nl</email>
    </contact>
    <investigator>
      <last_name>Robert Rissmann, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

